Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
76.35
+0.55 (+0.73%)
Official Closing Price
Updated: 4:15 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants
January 02, 2024
Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD
Via
Benzinga
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
December 31, 2023
Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program....
Via
Talk Markets
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
December 29, 2023
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc.
Via
Benzinga
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
December 29, 2023
The major indexes boast big annual gains with the Dow at record highs.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
December 28, 2023
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.
Via
Benzinga
Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry
December 26, 2023
Via
Benzinga
Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies
December 26, 2023
Via
Benzinga
Why Is Blood Purification Focused CytoSorbents Trading Lower Today?
December 28, 2023
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the...
Via
Benzinga
The Decline In Global Bond Yields Supports Stock Indices
December 28, 2023
A decline in global bond yields is lending support to stocks on optimism that global central banks will start cutting interest rates next year.
Via
Talk Markets
Topics
Bonds
Exposures
Debt Markets
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
December 27, 2023
With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.
Via
InvestorPlace
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
December 27, 2023
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole...
Via
Benzinga
Investor Sentiment Improves; Dow Jumps Over 150 Points
December 27, 2023
The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme Greed" zone on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
December 26, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher
December 26, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
December 26, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Crude Oil Rises Over 3%; US Home Prices Increase In October
December 26, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.34% to 37,511.87 while the NASDAQ rose 0.43% to 15,057.13. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
US Stocks Set To Start Final Trading Week Of Year On Positive Note As Santa Claus Rally Gets Going: Analyst Confident Of Market Finishing Year At Highs
December 26, 2023
Stocks appear on track to start Tuesday's session on a positive note amid positive expectations concerning interest rates and economy.
Via
Benzinga
AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies
December 26, 2023
AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Gracell Biotechnologies Inc (NASDAQ: GRCL), further strengthening AstraZeneca's cell therapy portfolio.
Via
Benzinga
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
December 26, 2023
From
AstraZeneca
Via
Business Wire
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential
December 22, 2023
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am
Via
Benzinga
Exposures
Product Safety
New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment
December 22, 2023
Friday, FDA approved AstraZeneca
Via
Benzinga
Exposures
Product Safety
These 3 Big Pharma Stocks Are Making Big Plays With AI
December 22, 2023
Opportunity is in the air with AI, and these pharma giants are seizing the moment.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
December 21, 2023
From
AstraZeneca
Via
Business Wire
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
December 21, 2023
Which weight-loss stocks are good buys today?
Via
The Motley Fool
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
December 20, 2023
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis...
Via
Benzinga
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
December 20, 2023
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n
Via
Benzinga
Exposures
COVID-19
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?
December 19, 2023
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the
Via
Benzinga
Why Is Compugen (CGEN) Stock Up 189% Today?
December 19, 2023
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.
Via
InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc. (NYSE - EGLE), Icosavax, Inc. (Nasdaq - ICVX), Evofem Biosciences, Inc. (OTC - EVFM), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
December 18, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
December 18, 2023
2024 is going to be a sizzler in the biopharma sector.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.